These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 30245304)

  • 1. SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment.
    Bianconi D; Herac M; Spies D; Kieler M; Brettner R; Unseld M; Fürnkranz K; Famler B; Schmeidl M; Minichsdorfer C; Zielinski C; Heller G; Prager GW
    Transl Oncol; 2019 Jan; 12(1):15-23. PubMed ID: 30245304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant nab-paclitaxel plus gemcitabine
    Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
    World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis.
    de Jesus VHF; Riechelmann RP
    Ecancermedicalscience; 2021; 15():1276. PubMed ID: 34567261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
    Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
    Front Oncol; 2020; 10():1112. PubMed ID: 32850319
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
    Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
    J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes of adjuvant gemcitabine
    Kang S; Yoo C; Lee SH; Oh D; Song TJ; Lee SS; Jeong JH; Park DH; Seo DW; Park JH; Hwang DW; Song KB; Lee JH; Lee W; Kwak BJ; Hong S; Chang HM; Ryoo BY; Kim KP; Kim SC
    Ther Adv Med Oncol; 2022; 14():17588359221097190. PubMed ID: 35571606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
    Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
    Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study.
    Striefler JK; Riess H; Lohneis P; Bischoff S; Kurreck A; Modest DP; Bahra M; Oettle H; Sinn M; Bläker H; Denkert C; Stintzing S; Sinn BV; Pelzer U
    Front Oncol; 2021; 11():670396. PubMed ID: 34386419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.
    Kurimoto M; Kimura M; Usami E; Iwai M; Hirose T; Kawachi S; Yoshimura T
    Mol Clin Oncol; 2017 Jul; 7(1):125-130. PubMed ID: 28685089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.
    Bachet JB; Maréchal R; Demetter P; Bonnetain F; Cros J; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
    Eur J Cancer; 2013 Aug; 49(12):2643-53. PubMed ID: 23726265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials.
    Ormanns S; Haas M; Baechmann S; Altendorf-Hofmann A; Remold A; Quietzsch D; Clemens MR; Bentz M; Geissler M; Lambertz H; Kruger S; Kirchner T; Heinemann V; Boeck S
    Br J Cancer; 2016 Dec; 115(12):1520-1529. PubMed ID: 27802454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment.
    Le Large TYS; El Hassouni B; Funel N; Kok B; Piersma SR; Pham TV; Olive KP; Kazemier G; van Laarhoven HWM; Jimenez CR; Bijlsma MF; Giovannetti E
    Ther Adv Med Oncol; 2019; 11():1758835919841233. PubMed ID: 31205498
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
    Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells.
    Huang B; Wang J; Chen Q; Qu C; Zhang J; Chen E; Zhang Y; Wang Y; Ni L; Liang T
    Am J Transl Res; 2019; 11(1):473-485. PubMed ID: 30788003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma.
    Stubbe BE; Henriksen SD; Madsen PH; Larsen AC; Krarup HB; Pedersen IS; Johansen MN; Thorlacius-Ussing O
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients.
    Ning Z; Xie J; Chen Q; Zhang C; Xu L; Song L; Meng Z
    Onco Targets Ther; 2019; 12():1021-1029. PubMed ID: 30774386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nagashima-type palmoplantar keratosis patients harboring SERPINB7 and SERPINA12 variants.
    Jiang X; Yang C; Wang H; Cai L; Lin Z
    J Dermatol; 2024 Jul; ():. PubMed ID: 39034590
    [No Abstract]   [Full Text] [Related]  

  • 19. Dissection of an impact of VDR and RXRA on the genomic activity of 1,25(OH)
    Olszewska AM; Nowak JI; Myszczynski K; Słominski A; Żmijewski MA
    Mol Cell Endocrinol; 2024 Mar; 582():112124. PubMed ID: 38123121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterocellular N-cadherin junctions enable nontransformed cells to inhibit the growth of adjacent transformed cells.
    Sheehan SA; Retzbach EP; Shen Y; Krishnan H; Goldberg GS
    Cell Commun Signal; 2022 Feb; 20(1):19. PubMed ID: 35177067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.